These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8229737)

  • 21. Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure.
    Shen YT; Wiedmann RT; Greenland BD; Lynch JJ; Grossman W
    Cardiovasc Res; 1998 Aug; 39(2):413-22. PubMed ID: 9798526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction.
    Wagner F; Yeter R; Bisson S; Siniawski H; Hetzer R
    Crit Care Med; 2003 May; 31(5):1421-8. PubMed ID: 12771613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative hemodynamic effects of MK-422, a converting enzyme inhibitor, and a renin inhibitor in dogs with acute left ventricular failure.
    Sweet CS; Ludden CT; Frederick CM; Bush LR; Ribeiro LG
    J Cardiovasc Pharmacol; 1984; 6(6):1067-75. PubMed ID: 6084762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction.
    Marie C; Mossiat C; Lecomte JM; Schwartz JC; Bralet J
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1324-31. PubMed ID: 8531099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
    Zhang X; Recchia FA; Bernstein R; Xu X; Nasjletti A; Hintze TH
    J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia.
    Chodjania Y; Tharaux PL; Ragueneau I; Dussaule JC; Picker JL; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 2002 Jun; 71(6):468-78. PubMed ID: 12087350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction.
    Ahmad M; White R; Tan J; Huang BS; Leenen FH
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):565-72. PubMed ID: 18496146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients.
    Johnson AG; Pearce GL; Danoff TM
    J Hum Hypertens; 2006 Jul; 20(7):496-503. PubMed ID: 16543907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
    Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
    Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
    Seymour AA; Abboa-Offei BE; Smith PL; Mathers PD; Asaad MM; Rogers WL
    Clin Exp Pharmacol Physiol; 1995 Jan; 22(1):63-9. PubMed ID: 7768036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
    Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
    Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.
    Margulies KB; Perrella MA; McKinley LJ; Burnett JC
    J Clin Invest; 1991 Nov; 88(5):1636-42. PubMed ID: 1658047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats.
    Trippodo NC; Gabel RA; Harvey CM; Asaad MM; Rogers WL
    J Cardiovasc Pharmacol; 1991 Sep; 18(3):308-16. PubMed ID: 1720829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene.
    Wegner M; Hirth-Dietrich C; Knorr A; Dressel J; Ganten D; Stasch JP
    Hypertens Res; 1996 Sep; 19(3):151-9. PubMed ID: 8891743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel JB; Roques BP
    J Med Chem; 1994 Apr; 37(8):1070-83. PubMed ID: 8164250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal and depressor activity of C-natriuretic peptide in conscious monkeys: effects of enzyme inhibitors.
    Seymour AA; Mathers PD; Abboa-Offei BE; Asaad MM; Weber H
    J Cardiovasc Pharmacol; 1996 Sep; 28(3):397-401. PubMed ID: 8877586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
    Fournié-Zaluski MC; Gonzalez W; Turcaud S; Pham I; Roques BP; Michel JB
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):4072-6. PubMed ID: 8171037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
    Ferro CJ; Spratt JC; Haynes WG; Webb DJ
    Circulation; 1998 Jun; 97(23):2323-30. PubMed ID: 9639376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure.
    Seymour AA; Asaad MM; Lanoce VM; Fennell SA; Cheung HS; Rogers WL
    Cardiovasc Res; 1993 Jun; 27(6):1015-23. PubMed ID: 8221758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.